FGL1 and lung carcinoma: Targeting both PD-L1 and FGL1 can enhance the immune response and anti-cancer effects in lung cancer [12], making FGL1 a promising biomarker for predicting the efficacy of PD-1/PD-L1 therapy as a novel immunotherapy target [13].